News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunotech Laboratories Announces Successful Completion Of Phase 1 And Phase 2 Field Trials Of The Company’s Patented Treatment Of The HIV/AIDS And Hepatitis C Viruses



8/28/2014 10:41:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MONROVIA, Calif.--(BUSINESS WIRE)--Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG (“IMMB-BG”) a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization (“CRO”) to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES